Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis

Direct oral anticoagulants (DOACs) have become widely used for the prevention of stroke in nonvalvular atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE). Warfarin, the standard of care prior to DOACs, requires monitoring and dose adjustment to ensure patients remain appr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of managed care & specialty pharmacy 2022-11, Vol.28 (11), p.1304-1315
Hauptverfasser: Karnick, Cameron, Modany, Ashley, McGraw, Molly, Ludwig, Justin, Marr, David, Hammonds, Tracy, Good, Chester B, Culley, Eric
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1315
container_issue 11
container_start_page 1304
container_title Journal of managed care & specialty pharmacy
container_volume 28
creator Karnick, Cameron
Modany, Ashley
McGraw, Molly
Ludwig, Justin
Marr, David
Hammonds, Tracy
Good, Chester B
Culley, Eric
description Direct oral anticoagulants (DOACs) have become widely used for the prevention of stroke in nonvalvular atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE). Warfarin, the standard of care prior to DOACs, requires monitoring and dose adjustment to ensure patients remain appropriately anticoagulated. DOACs do not require monitoring but are significantly more expensive. We sought to examine real-world effectiveness and costs of DOACs and warfarin in patients with AF and VTE. To examine clinical and economic outcomes. The clinical objectives were to determine the bleeding and thrombotic event rates associated with DOACs vs warfarin. The economic objectives were to determine the cost associated with these events, as well as the all-cause medical and pharmacy costs associated with DOACs vs warfarin. This analysis was an observational, propensity-matched comparison of retrospective medical and pharmacy claims data for members enrolled in an integrated health plan between October 1, 2015, and September 30, 2020. Members who were older than 18 years of age with at least 1 30-day supply of warfarin or a DOAC filled within 30 days of a new diagnosis of VTE or nonvalvular AF were eligible for the analysis. Cox hazard ratios were used to compare differences in clinical outcomes, where paired t-tests were used to evaluate economic outcomes. After matching, there were 893 patients in each group. Among matched members, warfarin was associated with increased risk of nonmajor bleeds relative to apixaban (hazard ratio [HR] = 1.526; = 0.0048) and increased risk of pulmonary embolism relative to both DOACs (apixaban: HR = 1.941 [ = 0.0328]; rivaroxaban: HR = 1.833 [ = 0.0489]). No statistically significant difference was observed in hospitalizations or in length of stay between warfarin and either DOAC. The difference-in-difference (DID) in total costs of care per member per month for apixaban and rivaroxaban relative to warfarin were $801.64 ( = 0.0178) and $534.23 ( = 0.0998) more, respectively. DID in VTE-related cost for apixaban was $177.09 less, relative to warfarin ( = 0.0098). DID in all-cause pharmacy costs for apixaban and rivaroxaban relative to warfarin were $342.47 ( < 0.0001) and $386.42 ( < 0.001) more, respectively. Warfarin use was associated with a significant decrease in total cost of care despite a significant increase in VTE-related costs vs apixaban. Warfarin was also associated with a significant increase in other nonmajor bleed
doi_str_mv 10.18553/jmcp.2022.28.11.1304
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10372967</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36282935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-9754d94f8f39072f978481de52d2632131bc029cbc0065f39bcb28dff7194d33</originalsourceid><addsrcrecordid>eNpVkV1PwyAUhonRODP3EzT8gVY4lJZ6Y5bFr2SJN7snjNLJ0kJTupnd-stlHy56AyfhfV_OOQ9Cd5SkVHDOHtat7lIgACmIlNKUMpJdoBtgRZ5QwuDyVBOekRGahLAmhADjuaDsGo1YDgJKxm_Q98y3nept8A77GvdGNcmX75sK68Y6q1WDlauw0d751mrsN4P2rQnYOtypwRo3hOjSxm6tW2HfHwyD1V6tNk2swiOeRsHQ-9AZPditicnKtiHKVLMLNtyiq1o1wUxO9xgtXp4Xs7dk_vH6PpvOE81yPiRlwbOqzGpRs5IUUJeFyAStDIcKcgaU0aUmUOp4kpxH0VIvQVR1XdAyqxgbo6djbLdZtqbSsfPYrOx626p-J72y8v-Ls59y5bcy7rOAMi9iAj8m6DhM6E19NlMiD1zknovcc5EgJKVyzyX67v_-fHb9UmA_wc6OTw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis</title><source>MEDLINE</source><source>PubMed Central</source><creator>Karnick, Cameron ; Modany, Ashley ; McGraw, Molly ; Ludwig, Justin ; Marr, David ; Hammonds, Tracy ; Good, Chester B ; Culley, Eric</creator><creatorcontrib>Karnick, Cameron ; Modany, Ashley ; McGraw, Molly ; Ludwig, Justin ; Marr, David ; Hammonds, Tracy ; Good, Chester B ; Culley, Eric</creatorcontrib><description>Direct oral anticoagulants (DOACs) have become widely used for the prevention of stroke in nonvalvular atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE). Warfarin, the standard of care prior to DOACs, requires monitoring and dose adjustment to ensure patients remain appropriately anticoagulated. DOACs do not require monitoring but are significantly more expensive. We sought to examine real-world effectiveness and costs of DOACs and warfarin in patients with AF and VTE. To examine clinical and economic outcomes. The clinical objectives were to determine the bleeding and thrombotic event rates associated with DOACs vs warfarin. The economic objectives were to determine the cost associated with these events, as well as the all-cause medical and pharmacy costs associated with DOACs vs warfarin. This analysis was an observational, propensity-matched comparison of retrospective medical and pharmacy claims data for members enrolled in an integrated health plan between October 1, 2015, and September 30, 2020. Members who were older than 18 years of age with at least 1 30-day supply of warfarin or a DOAC filled within 30 days of a new diagnosis of VTE or nonvalvular AF were eligible for the analysis. Cox hazard ratios were used to compare differences in clinical outcomes, where paired t-tests were used to evaluate economic outcomes. After matching, there were 893 patients in each group. Among matched members, warfarin was associated with increased risk of nonmajor bleeds relative to apixaban (hazard ratio [HR] = 1.526; = 0.0048) and increased risk of pulmonary embolism relative to both DOACs (apixaban: HR = 1.941 [ = 0.0328]; rivaroxaban: HR = 1.833 [ = 0.0489]). No statistically significant difference was observed in hospitalizations or in length of stay between warfarin and either DOAC. The difference-in-difference (DID) in total costs of care per member per month for apixaban and rivaroxaban relative to warfarin were $801.64 ( = 0.0178) and $534.23 ( = 0.0998) more, respectively. DID in VTE-related cost for apixaban was $177.09 less, relative to warfarin ( = 0.0098). DID in all-cause pharmacy costs for apixaban and rivaroxaban relative to warfarin were $342.47 ( &lt; 0.0001) and $386.42 ( &lt; 0.001) more, respectively. Warfarin use was associated with a significant decrease in total cost of care despite a significant increase in VTE-related costs vs apixaban. Warfarin was also associated with a significant increase in other nonmajor bleeds relative to apixaban, as well as a significant increase in pulmonary embolism relative to both DOACs. Warfarin was associated with a significant reduction in all-cause pharmacy cost compared with either DOAC. The authors of this study have nothing to disclose.</description><identifier>ISSN: 2376-0540</identifier><identifier>EISSN: 2376-1032</identifier><identifier>DOI: 10.18553/jmcp.2022.28.11.1304</identifier><identifier>PMID: 36282935</identifier><language>eng</language><publisher>United States: Academy of Managed Care Pharmacy</publisher><subject>Administration, Oral ; Anticoagulants - adverse effects ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Hemorrhage ; Humans ; Infant ; Insurance Claim Review ; Pulmonary Embolism - chemically induced ; Pulmonary Embolism - complications ; Pulmonary Embolism - prevention &amp; control ; Pyridones - adverse effects ; Retrospective Studies ; Rivaroxaban - adverse effects ; Stroke - etiology ; Stroke - prevention &amp; control ; Venous Thromboembolism - prevention &amp; control ; Warfarin - adverse effects</subject><ispartof>Journal of managed care &amp; specialty pharmacy, 2022-11, Vol.28 (11), p.1304-1315</ispartof><rights>Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-9754d94f8f39072f978481de52d2632131bc029cbc0065f39bcb28dff7194d33</citedby><cites>FETCH-LOGICAL-c365t-9754d94f8f39072f978481de52d2632131bc029cbc0065f39bcb28dff7194d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372967/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372967/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36282935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karnick, Cameron</creatorcontrib><creatorcontrib>Modany, Ashley</creatorcontrib><creatorcontrib>McGraw, Molly</creatorcontrib><creatorcontrib>Ludwig, Justin</creatorcontrib><creatorcontrib>Marr, David</creatorcontrib><creatorcontrib>Hammonds, Tracy</creatorcontrib><creatorcontrib>Good, Chester B</creatorcontrib><creatorcontrib>Culley, Eric</creatorcontrib><title>Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis</title><title>Journal of managed care &amp; specialty pharmacy</title><addtitle>J Manag Care Spec Pharm</addtitle><description>Direct oral anticoagulants (DOACs) have become widely used for the prevention of stroke in nonvalvular atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE). Warfarin, the standard of care prior to DOACs, requires monitoring and dose adjustment to ensure patients remain appropriately anticoagulated. DOACs do not require monitoring but are significantly more expensive. We sought to examine real-world effectiveness and costs of DOACs and warfarin in patients with AF and VTE. To examine clinical and economic outcomes. The clinical objectives were to determine the bleeding and thrombotic event rates associated with DOACs vs warfarin. The economic objectives were to determine the cost associated with these events, as well as the all-cause medical and pharmacy costs associated with DOACs vs warfarin. This analysis was an observational, propensity-matched comparison of retrospective medical and pharmacy claims data for members enrolled in an integrated health plan between October 1, 2015, and September 30, 2020. Members who were older than 18 years of age with at least 1 30-day supply of warfarin or a DOAC filled within 30 days of a new diagnosis of VTE or nonvalvular AF were eligible for the analysis. Cox hazard ratios were used to compare differences in clinical outcomes, where paired t-tests were used to evaluate economic outcomes. After matching, there were 893 patients in each group. Among matched members, warfarin was associated with increased risk of nonmajor bleeds relative to apixaban (hazard ratio [HR] = 1.526; = 0.0048) and increased risk of pulmonary embolism relative to both DOACs (apixaban: HR = 1.941 [ = 0.0328]; rivaroxaban: HR = 1.833 [ = 0.0489]). No statistically significant difference was observed in hospitalizations or in length of stay between warfarin and either DOAC. The difference-in-difference (DID) in total costs of care per member per month for apixaban and rivaroxaban relative to warfarin were $801.64 ( = 0.0178) and $534.23 ( = 0.0998) more, respectively. DID in VTE-related cost for apixaban was $177.09 less, relative to warfarin ( = 0.0098). DID in all-cause pharmacy costs for apixaban and rivaroxaban relative to warfarin were $342.47 ( &lt; 0.0001) and $386.42 ( &lt; 0.001) more, respectively. Warfarin use was associated with a significant decrease in total cost of care despite a significant increase in VTE-related costs vs apixaban. Warfarin was also associated with a significant increase in other nonmajor bleeds relative to apixaban, as well as a significant increase in pulmonary embolism relative to both DOACs. Warfarin was associated with a significant reduction in all-cause pharmacy cost compared with either DOAC. The authors of this study have nothing to disclose.</description><subject>Administration, Oral</subject><subject>Anticoagulants - adverse effects</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Infant</subject><subject>Insurance Claim Review</subject><subject>Pulmonary Embolism - chemically induced</subject><subject>Pulmonary Embolism - complications</subject><subject>Pulmonary Embolism - prevention &amp; control</subject><subject>Pyridones - adverse effects</subject><subject>Retrospective Studies</subject><subject>Rivaroxaban - adverse effects</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention &amp; control</subject><subject>Venous Thromboembolism - prevention &amp; control</subject><subject>Warfarin - adverse effects</subject><issn>2376-0540</issn><issn>2376-1032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV1PwyAUhonRODP3EzT8gVY4lJZ6Y5bFr2SJN7snjNLJ0kJTupnd-stlHy56AyfhfV_OOQ9Cd5SkVHDOHtat7lIgACmIlNKUMpJdoBtgRZ5QwuDyVBOekRGahLAmhADjuaDsGo1YDgJKxm_Q98y3nept8A77GvdGNcmX75sK68Y6q1WDlauw0d751mrsN4P2rQnYOtypwRo3hOjSxm6tW2HfHwyD1V6tNk2swiOeRsHQ-9AZPditicnKtiHKVLMLNtyiq1o1wUxO9xgtXp4Xs7dk_vH6PpvOE81yPiRlwbOqzGpRs5IUUJeFyAStDIcKcgaU0aUmUOp4kpxH0VIvQVR1XdAyqxgbo6djbLdZtqbSsfPYrOx626p-J72y8v-Ls59y5bcy7rOAMi9iAj8m6DhM6E19NlMiD1zknovcc5EgJKVyzyX67v_-fHb9UmA_wc6OTw</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Karnick, Cameron</creator><creator>Modany, Ashley</creator><creator>McGraw, Molly</creator><creator>Ludwig, Justin</creator><creator>Marr, David</creator><creator>Hammonds, Tracy</creator><creator>Good, Chester B</creator><creator>Culley, Eric</creator><general>Academy of Managed Care Pharmacy</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202211</creationdate><title>Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis</title><author>Karnick, Cameron ; Modany, Ashley ; McGraw, Molly ; Ludwig, Justin ; Marr, David ; Hammonds, Tracy ; Good, Chester B ; Culley, Eric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-9754d94f8f39072f978481de52d2632131bc029cbc0065f39bcb28dff7194d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Administration, Oral</topic><topic>Anticoagulants - adverse effects</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Infant</topic><topic>Insurance Claim Review</topic><topic>Pulmonary Embolism - chemically induced</topic><topic>Pulmonary Embolism - complications</topic><topic>Pulmonary Embolism - prevention &amp; control</topic><topic>Pyridones - adverse effects</topic><topic>Retrospective Studies</topic><topic>Rivaroxaban - adverse effects</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention &amp; control</topic><topic>Venous Thromboembolism - prevention &amp; control</topic><topic>Warfarin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karnick, Cameron</creatorcontrib><creatorcontrib>Modany, Ashley</creatorcontrib><creatorcontrib>McGraw, Molly</creatorcontrib><creatorcontrib>Ludwig, Justin</creatorcontrib><creatorcontrib>Marr, David</creatorcontrib><creatorcontrib>Hammonds, Tracy</creatorcontrib><creatorcontrib>Good, Chester B</creatorcontrib><creatorcontrib>Culley, Eric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of managed care &amp; specialty pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karnick, Cameron</au><au>Modany, Ashley</au><au>McGraw, Molly</au><au>Ludwig, Justin</au><au>Marr, David</au><au>Hammonds, Tracy</au><au>Good, Chester B</au><au>Culley, Eric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis</atitle><jtitle>Journal of managed care &amp; specialty pharmacy</jtitle><addtitle>J Manag Care Spec Pharm</addtitle><date>2022-11</date><risdate>2022</risdate><volume>28</volume><issue>11</issue><spage>1304</spage><epage>1315</epage><pages>1304-1315</pages><issn>2376-0540</issn><eissn>2376-1032</eissn><abstract>Direct oral anticoagulants (DOACs) have become widely used for the prevention of stroke in nonvalvular atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE). Warfarin, the standard of care prior to DOACs, requires monitoring and dose adjustment to ensure patients remain appropriately anticoagulated. DOACs do not require monitoring but are significantly more expensive. We sought to examine real-world effectiveness and costs of DOACs and warfarin in patients with AF and VTE. To examine clinical and economic outcomes. The clinical objectives were to determine the bleeding and thrombotic event rates associated with DOACs vs warfarin. The economic objectives were to determine the cost associated with these events, as well as the all-cause medical and pharmacy costs associated with DOACs vs warfarin. This analysis was an observational, propensity-matched comparison of retrospective medical and pharmacy claims data for members enrolled in an integrated health plan between October 1, 2015, and September 30, 2020. Members who were older than 18 years of age with at least 1 30-day supply of warfarin or a DOAC filled within 30 days of a new diagnosis of VTE or nonvalvular AF were eligible for the analysis. Cox hazard ratios were used to compare differences in clinical outcomes, where paired t-tests were used to evaluate economic outcomes. After matching, there were 893 patients in each group. Among matched members, warfarin was associated with increased risk of nonmajor bleeds relative to apixaban (hazard ratio [HR] = 1.526; = 0.0048) and increased risk of pulmonary embolism relative to both DOACs (apixaban: HR = 1.941 [ = 0.0328]; rivaroxaban: HR = 1.833 [ = 0.0489]). No statistically significant difference was observed in hospitalizations or in length of stay between warfarin and either DOAC. The difference-in-difference (DID) in total costs of care per member per month for apixaban and rivaroxaban relative to warfarin were $801.64 ( = 0.0178) and $534.23 ( = 0.0998) more, respectively. DID in VTE-related cost for apixaban was $177.09 less, relative to warfarin ( = 0.0098). DID in all-cause pharmacy costs for apixaban and rivaroxaban relative to warfarin were $342.47 ( &lt; 0.0001) and $386.42 ( &lt; 0.001) more, respectively. Warfarin use was associated with a significant decrease in total cost of care despite a significant increase in VTE-related costs vs apixaban. Warfarin was also associated with a significant increase in other nonmajor bleeds relative to apixaban, as well as a significant increase in pulmonary embolism relative to both DOACs. Warfarin was associated with a significant reduction in all-cause pharmacy cost compared with either DOAC. The authors of this study have nothing to disclose.</abstract><cop>United States</cop><pub>Academy of Managed Care Pharmacy</pub><pmid>36282935</pmid><doi>10.18553/jmcp.2022.28.11.1304</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2376-0540
ispartof Journal of managed care & specialty pharmacy, 2022-11, Vol.28 (11), p.1304-1315
issn 2376-0540
2376-1032
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10372967
source MEDLINE; PubMed Central
subjects Administration, Oral
Anticoagulants - adverse effects
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Hemorrhage
Humans
Infant
Insurance Claim Review
Pulmonary Embolism - chemically induced
Pulmonary Embolism - complications
Pulmonary Embolism - prevention & control
Pyridones - adverse effects
Retrospective Studies
Rivaroxaban - adverse effects
Stroke - etiology
Stroke - prevention & control
Venous Thromboembolism - prevention & control
Warfarin - adverse effects
title Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20real-world%20clinical%20and%20economic%20outcomes%20in%20patients%20receiving%20oral%20anticoagulants:%20A%20retrospective%20claims%20analysis&rft.jtitle=Journal%20of%20managed%20care%20&%20specialty%20pharmacy&rft.au=Karnick,%20Cameron&rft.date=2022-11&rft.volume=28&rft.issue=11&rft.spage=1304&rft.epage=1315&rft.pages=1304-1315&rft.issn=2376-0540&rft.eissn=2376-1032&rft_id=info:doi/10.18553/jmcp.2022.28.11.1304&rft_dat=%3Cpubmed_cross%3E36282935%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36282935&rfr_iscdi=true